Olmesartanmedoxomil Hec Pharm (Olmesartan Medoxomil)

Olmesartan medoxil, the active ingredient in Olmesartanmedoxomil Hec Pharm, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension primarily in adult patients. GNH USA supplies Olmesartanmedoxomil Hec Pharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartanmedoxomil Hec Pharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil is used to manage high blood pressure by acting on the renin‑angiotensin system.

- Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. - Heart failure: used as part of combination therapy to improve cardiac output and symptoms. - Diabetic nephropathy: helps slow progression of kidney damage associated with diabetes. - Post‑myocardial infarction: aids in blood‑pressure control to lower the chance of recurrent events. - Stroke prevention: contributes to long‑term risk reduction in patients with prior cerebrovascular events.

Olmesartan medoxil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea - Upper respiratory tract infection

Serious or Rare Side Effects: - Angio‑edema - Hyperkalemia - Acute kidney injury - Severe hypotension - Liver enzyme elevation - Allergic skin reactions

When prescribing Olmesartan medoxil, clinicians should consider several safety aspects.

- Renal function: assess baseline kidney function and monitor periodically. - Electrolytes: check serum potassium, especially if combined with potassium‑sparing diuretics. - Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity. - Elderly patients: start at lower doses and monitor for orthostatic hypotension. - Drug interactions: review concomitant medications that affect the renin‑angiotensin system. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Olmesartan medoxil can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren: combined use in diabetic patients may increase risk of renal impairment. - Potassium‑supplemented products: may cause dangerous hyper‑kalemia. - NSAIDs: can blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypotensive effect; monitor blood pressure. - Lithium: may increase lithium levels; check serum concentrations. - ACE inhibitors or other ARBs: additive risk of hyper‑kalemia and renal dysfunction. - CYP450 inhibitors: may modestly increase olmesartan exposure.